Mizuho analyst Ann Hynes reiterated an 'Outperform' rating on Quest Diagnostics and increased its price target from $235 to $260. This indicates a positive outlook from the analyst, suggesting potential upside for the stock.
Mizuho analyst Ann Hynes maintained an 'Outperform' rating on Quest Diagnostics (DGX) and raised the price target from $235 to $260. This analyst action signals continued confidence in the company's performance and future prospects, which could lead to increased investor interest and a positive short-term price movement for DGX. The higher price target suggests that Mizuho sees significant upside potential, making it an opportunity for traders looking for stocks with positive analyst sentiment. Long-term implications depend on Quest Diagnostics' ability to meet or exceed these expectations, but in the short term, this news is generally bullish for the stock.